XBiotech Inc. (XBIT): R&D Expense
$47.39M
Year ended 2025-12-31
$40.94M
Trailing 12 months to 2026-06-30
+14.5%
3-year compound annual growth
+37.8%
5-year compound annual growth
+4.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $47.39M | +25.5% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $37.76M | +14.9% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $32.85M | +4.1% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $31.54M | +11.6% | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | $28.27M | +196.7% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $9.53M | -60.5% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $24.09M | +53.2% | 2022-03-15, From 2019-01-01 |
| 2018-12-31 | $15.72M | -40.5% | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | $26.42M | -37.8% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $42.49M | +35.7% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $31.31M | +118.5% | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | $14.33M | +80.6% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $7.93M | n/a | 2016-04-15, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| XBiotech Inc. (XBIT) | 2025-12-31 | $47.39M | +25.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Veradermics, Inc (MANE) | 2025-12-31 | $62.06M | +166.6% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $154.22M | +110.5% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $44.84M | -18.9% |
Compare XBIT, WHWK, OVID, CTMX side by side · Screen every company in Pharmaceutical Preparations ↗